A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objectives: Preliminary evidence suggested that doxycycline and rifampin might stop or slow the progression of Alzheimer's disease (AD). We carried out a randomized trial to confirm or refute these findings. Methods: A multicenter, blinded, randomized, 2 × 2 factorial controlled trial, set at 14 geriatric outpatient clinics in Canada. Four hundred and six patients with mild to moderate AD (standardized mini mental state examination (SMMSE) score 14–26) participated. The intervention was 12 months' treatment with doxycycline 100 mg twice daily + rifampin 300 mg daily or doxycycline 100 mg twice daily + placebo‐rifampin daily or rifampin 300 mg daily + placebo‐doxycycline twice daily or placebo‐doxycycline twice daily + placebo‐rifampin daily. Coprimary outcomes were the Standardized Alzheimer's Disease Assessment Scale‐Cognitive Subscale (SADAS‐cog) and the Clinical Dementia Rating Scale‐Sum of the Boxes (CDR‐SB). Secondary outcomes were the SMMSE, Quick mild cognitive impairment screen, Geriatric Depression Scale, Cornell Scale for Depression in Dementia, activities of daily living (Lawton Scale), and the Dysfunctional Behavior Rating Instrument frequency and reaction subscales. Results: There was a significant deterioration in SADAS‐cog over time with both rifampin and doxycycline in comparison with placebo. When the two were used together, there was no statistically significant decline/deterioration in comparison with placebo (n = 305). For the CDR‐SB, there were no significant effects of either rifampin or doxycycline. Secondary outcome results followed similar patterns. Conclusion: Twelve months' treatment with doxycycline or rifampin, alone or in combination, has no beneficial effects on cognition or function in AD. Copyright © 2012 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Cornell scale for depression in dementia
Alexopoulos, G. S., Abrams, R. C., Young, R. C., & Shamoian, C. A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90038-8 · Cited by 2,678
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 2×
“, 2004), inhibition of amyloid beta aggregation (Cherny et al., 2001; Ritchie et al., 2003; Aisen et al., 2004), and the increase in clearance of amyloid beta fibrils (Schenk et al.”
BackgroundRitchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 2×
“, 2004), inhibition of amyloid beta aggregation (Cherny et al., 2001; Ritchie et al., 2003; Aisen et al., 2004), and the increase in clearance of amyloid beta fibrils (Schenk et al.”
BackgroundThe method of minimization for allocation to clinical trials
Scott, N. W., McPherson, G. C., Ramsay, C. R., & Campbell, M. K. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00242-8 · Cited by 651 · cited 1×
“Randomization used the ‘minimization’ approach (Scott et al., 2002) that seeks to control for important prognostic factors at the point of randomization to minimize the difference between groups.”
Method(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.1.102 · Cited by 647
Self-citation
Cited by
Microbiota-Brain-Gut Axis and Neurodegenerative Diseases
Quigley, E. M. M. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0802-6 · Cited by 804
Antibiotics, gut microbiota, and Alzheimer’s disease
Angelucci, F., Cechova, K., Amlerova, J., & Hort, J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1494-4 · Cited by 454
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
Harris, S. A., & Harris, E. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142853 · Cited by 279
Effect of nutrition on neurodegenerative diseases. A systematic review
Bianchi, V. E., Herrera, P. F., & Laura, R. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1681088 · Cited by 249
“microbiota in AD patients the cognition improved [239,240] and oxidative stress in the brain decreased significantly activating SIRT-1 pathway [241].”
BackgroundAlzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
Kim, C. K., Lee, Y. R., Ong, L., Gold, M., Kalali, A., & Sarkar, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215699 · Cited by 241
“The following are examples where 594 no biomarkers were used to both screen patients 595 and monitor their response to treatment: nilvadip596 ine, a calcium channel blocker thought to increase 597 vascular blood flow, although APOE status was mea598 sured [50] (a sub-study to measure CSF A and tau 599 was discussed bu…”
MethodTime to test antibacterial therapy in Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Watling, M., & Imbimbo, B. P. (2019) · Brain · doi:10.1093/brain/awz244 · Cited by 161
Oral Microbiota and Alzheimer’s Disease: Do All Roads Lead to Rome?
Sureda, A., Daglia, M., Argüelles Castilla, S., Sanadgol, N., Fazel Nabavi, S., Khan, H., Belwal, T., Jeandet, P., Marchese, A., Pistollato, F., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104582 · Cited by 143
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Association of midlife antibiotic use with subsequent cognitive function in women
Mehta, R. S., Lochhead, P., Wang, Y., Ma, W., Nguyen, L. H., Kochar, B., Huttenhower, C., Grodstein, F., & Chan, A. T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264649 · Cited by 26
“Finally, in a multicenter randomized clinical trial among patients with Alzheimer’s disease, 12 months of treatment with antibiotics led to declines in cognitive scores compared to placebo [23].”
BackgroundLiu, Z., Wei, S., Chen, X., Liu, L., Wei, Z., Liao, Z., Wu, J., Li, Z., Zhou, H., & Wang, D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.833365 · Cited by 10
Metadata
- Authors
- Molloy, D. W., Standish, T. I., Zhou, Q., Guyatt, G., & The DARAD Study Group
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2012-06-21
- Volume
- 28
- Issue
- 5
- Pages
- 463-470
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W1836722617
- Cited by
- 128
- References
- 7
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.